Literature DB >> 8993409

Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons.

W A Banks1, D Uchida, A Arimura, A Somogyvári-Vigh, S Shioda.   

Abstract

PACAP is a member of the secretin/glucagon/VIP family of peptides and demonstrates neurotrophic and neuroprotective effects at very low concentrations. We have previously shown that PACAP crosses the BBB to a modest degree by way of a saturable transport system. PACAP is transported across the BBB as an intact peptide to enter the parenchymal space of the brain. We tested the possibility that this modest rate of transport would be sufficient to produce the low levels of PACAP needed in the brain to exert a neuroprotective effect against ischemia. We found that PACAP given intravenously could indeed prevent the death of CA1 hippocampal neurons, even if the administration of PACAP was delayed for 24 h after the ischemic event. We suggest that iv PACAP could be neuroprotective after stroke, cardiac arrest, and hypotensive episodes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8993409     DOI: 10.1111/j.1749-6632.1996.tb17489.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  24 in total

1.  Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.

Authors:  Yazhou Li; David Tweedie; Mark P Mattson; Harold W Holloway; Nigel H Greig
Journal:  J Neurochem       Date:  2010-04-02       Impact factor: 5.372

Review 2.  Secretin: Should we revisit its metabolic outcomes?

Authors:  D H St-Pierre; F Broglio
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

Review 3.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 4.  Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics.

Authors:  Lee E Eiden; Ki Ann Goosens; Kenneth A Jacobson; Lorenzo Leggio; Limei Zhang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

5.  Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion.

Authors:  Gabriella Horvath; Boglarka Racz; Dora Reglodi; Krisztina Kovacs; Peter Kiss; Ferenc Gallyas; Zita Bognar; Aliz Szabo; Tamas Magyarlaki; Eszter Laszlo; Andrea Lubics; Andrea Tamas; Gabor Toth; Peter Szakaly
Journal:  J Mol Neurosci       Date:  2010-03-16       Impact factor: 3.444

6.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Yoichi Aizawa; Atsushi Takaki; Kei Hodoyama; Sachiko Yofu; Hitoshi Hashimoto; Norihito Shintani; Akemichi Baba; Manfred Kopf; Yoichiro Iwakura; Kouhei Matsuda; Akira Arimura; Seiji Shioda
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice.

Authors:  Julie Deguil; François Chavant; Claire Lafay-Chebassier; Marie-Christine Pérault-Pochat; Bernard Fauconneau; Stéphanie Pain
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

Review 8.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

9.  Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion.

Authors:  Peter Szakaly; Peter Kiss; Andrea Lubics; Tamas Magyarlaki; Andrea Tamas; Boglarka Racz; Istvan Lengvari; Gabor Toth; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2008-05-14       Impact factor: 3.444

Review 10.  Role of PACAP in ischemic neural death.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2008-05-16       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.